跳到正文

#代谢/减重

今日 28 条
10月11日周日
  1. bioRxiv 预印本12

    产前应激通过中脑边缘系统改变和额纹状体功能障碍诱导性别二态性脑衰老

    一项bioRxiv预印本研究显示,不可预测的轻度产前应激使C57BL/6J小鼠子代出生体重降低并快速生长,伴随中枢胰岛素抵抗和海马信号缺陷。中年应激雄鼠出现快感缺失,老年进展为多动、刻板行为和持续空间记忆缺陷,与额纹状体加速衰退相关;中年应激雌鼠则表现为活动减少和焦虑降低,老年出现快感缺失但保留海马依赖记忆。

  2. bioRxiv 预印本10

    全基因组GxE图谱结合等位基因频率轨迹揭示近1万年来饮食依赖性选择信号

    研究将全基因组基因-环境交互(GxE)图谱与近1万年的等位基因频率轨迹结合,在45个独立位点中发现3个具显著定向选择特征的位点,分别与尿酸、LDL-C和胆固醇水平相关,其频率上升与加速点重叠于约4700-7200年前。选择相关GxE位点富集于尿酸相关变异及涉及肉类和奶酪消费的交互,饮食相关变异在各位点呈现一致的交互方向。全球人群分析显示衍生等位基因频率上升及时间模式广泛共享。

  3. bioRxiv 预印本22

    组成性雄烷受体(CAR)通过性别特异性肠道菌群互作抵御代谢功能障碍相关脂肪性肝病

    小鼠实验显示,组成性雄烷受体(CAR)以性别依赖方式抵御代谢功能障碍相关脂肪性肝病(MASLD)进展:雄性 Car-/- 小鼠在西方饮食14周后肝损伤、炎症和纤维化加重,胆汁酸、胆固醇及肠道菌群稳态紊乱,雌性则无此表型。共居与粪菌移植实验表明 Car+/+ 菌群可保护肝脏,而 Car-/- 菌群会被 Car+/+ 宿主重塑。人类队列中,晚期 MASLD 患者肝脏 CAR 表达下降。

  4. 梅斯医学 MedSci62

    欧洲多学会发布指导意见:瑞美替罗与司美格鲁肽在MASH靶向治疗中的应用策略

    欧洲肝病学会、欧洲糖尿病学会和欧洲肥胖症学会联合发布指导意见,为瑞美替罗与司美格鲁肽用于伴显著纤维化的非肝硬化性MASH提供实用推荐。意见提出应优先用无创性检测筛选治疗人群,无需肝活检即可启动治疗,并给出两药个体化选择、监测与停药路径。对于MASH相关代偿期肝硬化患者,在获得进一步数据前不推荐将两药作为MASH靶向治疗使用。

    推荐理由:摘译欧洲三学会共识,梳理瑞美替罗与司美格鲁肽在MASH治疗中的适用人群、监测与停药路径。

  5. 梅斯医学 MedSci62

    Nature:赵文婧/唐啸宇/牟相宇揭示肠道共生菌C15:0调控宿主脂质代谢新机制

    中山大学中山医学院赵文婧/牟相宇团队联合深圳湾实验室/深圳医学科学院唐啸宇团队在Nature发表研究,发现肠道共生菌B. uniformis产生的十五烷酸(PA,C15:0)可抑制肝脏胆固醇合成、促进循环LDL-C清除并减轻小鼠动脉粥样硬化。

    推荐理由:研究把肠道共生菌代谢物C15:0与肝脏HMGCR抑制、LDL-C清除连成一条完整机制链,可供理解菌群调控血脂的分子路径。

10月10日周六
  1. 梅斯医学 MedSci12

    糖尿病用药指南及专家共识解读——二甲双胍篇

    二甲双胍因降糖效果确切、安全性良好、兼具成本效益与明确长期心血管获益证据,被国内外权威指南一致推荐为2型糖尿病(T2DM)一线首选药物和联合治疗的基础用药。我国约80%的T2DM患者在非内分泌科室就诊,该解读回顾二甲双胍临床应用历程与最新指南推荐,并介绍其在妊娠期高血糖、多囊卵巢综合征等特殊人群中的规范用药,为非内分泌科室医师提供参考。

  2. 梅斯医学 MedSci22

    《Nature》研究:剔除饮食半胱氨酸一周内使小鼠体重下降30%,复食后迅速回弹

    《Nature》上线的一项研究显示,在Cse基因敲除小鼠中剔除饮食半胱氨酸(no-Cys diet)可使小鼠一周内体重下降30%,减重幅度高于异亮氨酸缺失组的27.4%,且复食后体重迅速回弹。机制上,半胱氨酸缺失引发GSH耗竭、ISR/OSR激活及肝脏CoA水平骤降(第2天减少30%、第7天仅剩25%),迫使机体转向脂肪氧化供能。

  3. Adam Feuerstein ✡️22

    Adam Feuerstein 认同 Peter Kolchinsky 的观点:市场应朝推出相对低价、低剂量的非处方 GLP-1 方向发展,用于减重或体重增加预防。

    引用Peter Kolchinsky@PeterKolchinsky

    I think the biggest market pharma will ever tackle will actually be weight gain PREVENTION. And the dynamics of this market are going to be very different from the medicalized weight loss market and require better, more convenient products. The race for that market has only just begun. We helped to pivot one of our companies, Terrestrial, to work in prevention (as well as weight loss), and their clinical progress now makes me comfortable sharing our thesis for the weight gain prevention space. They have a needle-free, room-temp stable microneedle patch where the microneedles are made of semaglutide. Apply it for a few min, the base of the needles dissolves leaving drug under the skin, and you can then throw away the patch. That’s the weekly dose. No sharps containers. Once drug is under skin, it behaves very similarly to regularly injected semaglutide. 505b2 path to market is derisked by all existing data on sema. But Terrestrial isn’t stopping at just getting approved for all same indications as sema. It’s also gunning to get it OTC and get weight gain prevention on the label, legitimizing what today is a common off-label use (so common that South Park parodied it). From a societal value, there may not be any single medical breakthrough that rivals what a needle-free, OTC QW GLP-1 can offer to humanity. Excess weight leads to so much disability, disease, cost, lost productivity, and early mortality. Doesn’t make sense for people to have to gain weight to then get help losing it. Makes more sense for them to get help quieting the hunger noise (drive to eat) so they can avoid gaining weight in the first place. Have doubts? No problem. Read the article and then decide. The key insight here is that an OTC needle-free GLP-1 is not simply some late comer to a mature category but actually the beginning of an entirely new market that is so large that it would be worth any consumer-focused company to pay attention and for any standard pharma to consider what it would take to pivot into this space. And if you have never experienced how a GLP-1 can quiet hunger noise, you’ll have a harder time relating. Young people with fast metabolisms will likely miss this. But someday they will say “holy crap, I get it!”. 60% of Americans are overweight or obese… the battle against weight gain is one most people are destined to lose without help. 3B people around the world are overweight/obese. This is a giant global market at even very low unit prices (eg $25/month). Enjoy the read. Godspeed Terrestial! The RA Capital team is really proud to support you.